Table 1 Baseline characteristics of patients (intention to treat population)
Parameter | Chemotherapy-gefitinib (PCG) (N = 44) (%) | Chemotherapy (PC) (N = 46) (%) | Total (N = 90) (%) | P-value |
|---|---|---|---|---|
Age (years) | ||||
Median (range) | 60.0 (44–72) | 59.0 (37–70) | 59.5 (37–72) | 0.678 |
Gender | ||||
Male | 35 (79.5) | 42 (91.3) | 77 (85.6) | |
Female | 9 (20.5) | 4 (8.7) | 13 (14.4) | 0.113 |
Smoking status | ||||
Smoker | 37 (84.1) | 44 (95.7) | 81 (90.0) | |
Non-smoker | 7 (15.9) | 2 (4.3) | 9 (10.0) | 0.087 |
ECOG status | ||||
ECOG 0 | 0 | 0 | 0 | |
ECOG 1 | 44 (100) | 46 (100) | 90 (100) | – |
Histological subtype | ||||
Adenocarcinoma | 24 (54.5) | 31 (67.4) | 55 (61.1) | |
Non-adenocarcinoma | 20 (45.5) | 15 (32.6) | 35 (38.9) | 0.211 |
EGFR mutation | ||||
Wild-type | 6 (13.6) | 3 (6.5) | 9 (10.0) | |
Unknown | 38 (86.4) | 43 (93.5) | 81 (90.0) | 0.157 |
Stage of disease | ||||
Stage IIIB | 8 (18.2) | 10 (21.7) | 18 (20.0) | |
Stage IV | 36 (81.8) | 36 (78.3) | 72 (80.0) | 0.673 |